Combining several signals in a biological pathway does not guarantee a larger beneficial outcome. Feedback, binding and tissue responses can make the result more complicated than a simple addition of effects.
A study in pigs investigated LR3 alone or alongside porcine GH and reported changes in growth characteristics and endogenous hormone measurements. LR3 reduced growth-related outcomes under those experimental conditions, illustrating that a predicted anabolic effect does not transfer uniformly across models.
A pathway diagram is not a combination trial
The paper does not prove that the same result would occur in humans. It does, however, undermine the claim that combining GH-related interventions must logically produce more useful growth.
A combination needs its own evidence. That includes the actual molecules, preparation, population, endpoint and safety assessment. Evidence for each ingredient separately is not automatically evidence for using them together.
The sampled Reddit question concerned adding LR3 to CJC/ipamorelin or alternating among them. The pig experiment studied neither that combination nor a human schedule. It therefore cannot tell a reader which sequence to use, and this article supplies none.
Endogenous hormone measurements must also be distinguished from the administered analogue. A change in one does not necessarily describe the full activity of the other.
For a clinical concern about growth-hormone function, the useful conversation is diagnostic and product-specific. A clinician can identify what is being assessed and whether an authorized treatment is indicated. A self-assembled stack can obscure those questions rather than answer them.
The evidence lesson is not that every combination necessarily fails. It is that “more signals” is a hypothesis, not a guaranteed benefit. Research in a whole organism can reveal responses that a simplified pathway story misses, and that uncertainty should be stated before a product combination is promoted.